Compare Quest Diagnostics Inc (DGX) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Fox Corp Class B — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while Fox Corp Class B trades at $55.42 (market cap $24.58B). The key difference: Quest Diagnostics Inc and Fox Corp Class B are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | FOX | |
|---|---|---|
Market Cap | $26.21B | $24.58B |
Sector | Health | Media |
52-Week High | $238.50 | $67.76 |
52-Week Low | $173.49 | $44.39 |
Enterprise Value | $31.97B | $27.94B |
Dividend Yield | 1.45% | 1.05% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
